Indication and important safety information INCRELEX (mecasermin) is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency* (IGFD), or with hormone (GH) gene deletion who have developed neutralizing antibodies to GH
Third, individual variation is substantial: patients with severe insulin resistance or significant mitochondrial dysfunction may respond at lower doses than metabolically healthy athletes
The dosages should be discussed with a clinician, wholl consider your weight loss goals, medical history, and drug tolerance
Let's break down each approach systematically
Plan your dose increase for a day when you can rest if needed
Retatrutide, in contrast, has been tested at doses up to 12 mg per week